In that context, the researchers examined the insurance claims of nearly 3,600 pregnancies among women taking GLP-1s, some of whom continued to do so during the first trimester of pregnancy and some of whom stopped
GLP-1 receptor agonists have transformed the management of obesity and type 2 diabetes in recent years
[14] [15] These medications are administered via subcutaneous injection (with the exception of oral semaglutide) at varying frequencies from daily to weekly, depending on the specific formulation
281 By reducing macrophage-mediated inflammatory responses, GLP-1RAs have the potential to alleviate symptoms of OA, including pain and joint stiffness
Notice: This product is intended strictly for research purposes
Patients on maintenance doses retained 70 to 85% of their peak weight loss at two years, compared to 40 to 60% retention for those who stopped completely but implemented lifestyle changes, and less than 30% for those who stopped without significant lifestyle modification
